US FDA Urged To Drop Snail Mail For IND Communications

Waiting for paper letters to arrive can delay drug development, companies contend, but moving completely to e-communication may be difficult for the FDA.

Letter Envelop Message Notification Concept
Industry representatives said the FDA should rely on email for formal communications and stop using snail mail. • Source: Shutterstock

Sponsors believe early drug development communication would improve if the US Food and Drug Administration eliminated the post office as a facilitator.

Not only would relying on electronic instead of paper communication modernize outdated practices within the agency, but also improve consistency...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA

More from Agency Leadership